Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.820
+0.010 (0.36%)
At close: Aug 14, 2026, 4:00 PM EDT
2.840
+0.020 (0.71%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $11.89M in the quarter ending June 30, 2026, with 232.31% growth. This brings the company's revenue in the last twelve months to $47.01M, up 20.83% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth.
Revenue (ttm)
$47.01M
Revenue Growth
+20.83%
P/S Ratio
9.21
Revenue / Employee
$540,287
Employees
87
Market Cap
433.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Fennec Pharmaceuticals | 59.22M |
| Prothena Corporation | 54.53M |
| Q32 Bio | 53.74M |
| X4 Pharmaceuticals | 15.85M |
| SL Science Holding | 3.27M |
| Inhibikase Therapeutics | 1.00 |
EDIT News
- 10 days ago - Editas Medicine reports Q2 EPS (15c), consensus (28c) - TheFly
- 10 days ago - Editas Medicine Announces Second Quarter 2026 Results and Business Updates - GlobeNewsWire
- 10 days ago - Editas Medicine Earnings release: Q2 2026 - Filings
- 10 days ago - Editas Medicine Quarterly report: Q2 2026 - Filings
- 11 days ago - Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D. - GlobeNewsWire
- 2 months ago - The Healthcare M&A Wave - Forbes
- 2 months ago - Editas Medicine Transcript: AGM 2026 - Transcripts
- 2 months ago - Editas Medicine Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts